Khan Nazleen F, Bykov Katsiaryna, Glynn Robert J, Vine Seanna M, Gagne Joshua J
Department of Epidemiology, Harvard T.H. Chan School of Public Health.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School.
Am J Epidemiol. 2025 Mar 4;194(3):674-679. doi: 10.1093/aje/kwae248.
Sulfamethoxazole/trimethoprim, a commonly used antibiotic, has been associated with opioid overdose in patients with long-term opioid use, based on a prior drug-drug interaction screening study. To evaluate whether this finding represents a false-positive signal due to potential confounding, we assessed the safety of sulfamethoxazole/trimethoprim relative to 2 comparable antibiotic treatments in patients receiving long-term opioid therapy. We used data from 4 large administrative claims databases spanning 2000-2019. The study population was restricted to patients aged 18 years or older with urinary tract infection and at least 90 days of continuous prescription opioid use who initiated sulfamethoxazole/trimethoprim, nitrofurantoin, or fluoroquinolone therapy. We used propensity score matching weights to adjust for confounding and Cox proportional hazards models to estimate weighted hazard ratios (HRs) and 95% CIs in a 30-day intention-to-treat analysis. Cumulative 30-day opioid overdose risk ranged between 0.04% and 0.12% across databases and did not differ between antibiotics. Relative to sulfamethoxazole/trimethoprim, the weighted HR of opioid overdose was 1.09 (95% CI, 0.79-1.50) for nitrofurantoin and 0.94 (95% CI, 0.68-1.31) for fluoroquinolones. Potential safety signals identified in high-throughput screening studies, especially for medication combinations with limited biologic plausibility of drug-drug interaction and high frequency of use, should be interpreted with caution. .
根据先前的药物相互作用筛查研究,常用抗生素磺胺甲恶唑/甲氧苄啶与长期使用阿片类药物的患者阿片类药物过量有关。为了评估这一发现是否由于潜在的混杂因素而代表假阳性信号,我们评估了磺胺甲恶唑/甲氧苄啶相对于另外两种可比抗生素治疗对接受长期阿片类药物治疗患者的安全性。我们使用了2000年至2019年期间4个大型行政索赔数据库的数据。研究人群仅限于年龄在18岁及以上、患有尿路感染且至少连续90天使用阿片类药物处方并开始使用磺胺甲恶唑/甲氧苄啶、呋喃妥因或氟喹诺酮治疗的患者。我们使用倾向评分匹配权重来调整混杂因素,并使用Cox比例风险模型在30天意向性分析中估计加权风险比(HR)和95%置信区间(CI)。各数据库中30天阿片类药物过量累积风险在0.04%至0.12%之间,且抗生素之间无差异。相对于磺胺甲恶唑/甲氧苄啶,呋喃妥因的阿片类药物过量加权HR为1.09(95%CI,0.79-1.50),氟喹诺酮为0.94(95%CI,0.68-1.31)。在高通量筛查研究中确定的潜在安全信号,尤其是对于药物相互作用生物学合理性有限且使用频率高的药物组合,应谨慎解读。